Novartis / Administrator Intellectual Property Department Provider Synergies L.L.C. / Provider Synergies L.L.C. / GlaxoSmithKline / Agency for Healthcare Research / Gilead Sciences / Schering-Plough / Bristol Myers Squibb / Alteon Inc. / /
Continent
Asia / /
Country
United States / /
Currency
CYP / pence / / /
Event
FDA Phase / Product Recall / Product Issues / /
IndustryTerm
enzyme systems / treatment for HBV / food / treatment of HIV / treatment for HIV / HBV therapy / tenofovir-containing products / treatment algorithm / /
MedicalCondition
chronic adefovir therapy / breakthrough virologic infection / HIV / HBV / HBeAg-negative chronic HBV infection / myopathy / liver failure / cirrhosis / Compensated liver disease / hepatitis B / Peripheral neuropathy / needle stick injury / numbness / HBeAg-negative disease / hepatitis / Agents Adverse Effects Drug Asthenia/ Malaise/ Fatigue Headache Abdominal pain Nausea/ Vomiting Diarrhea ALT / renal dysfunction / liver disease / infections / hepatic decompensation / HIV infection / unrelated cancer / necrosis / cancer / HBV infection / yrs hepatitis B / disease / chronic HBV infections / acute HBV infection / hepatocellular carcinoma / previously demonstrated hypersensitivity / chronic HBV infection / chronic infections / viral infections / lactic acidosis / HBV infections / drug abuse / histologically active disease / acute HBV infections / infection / inflammation / chronic hepatitis B / recommended testing for HBV in the following patient groups / /
MedicalTreatment
immunization / highly active antiretroviral therapy / vaccination / chemotherapy / antiviral therapy / HAART / drug therapy / /
Movie
Half-Life / /
Organization
Pharmacy and Therapeutics committee / Centers for Disease Control and Prevention / Advisory Committee on Immunization Practices / American Association for the Study of Liver Diseases / FDA / Medicaid Agency / Agency for Healthcare Research and Quality / /
Microsoft Word - Hepatitis B Agents Nov 09.doc